Clinical Trial Data and AMA Resolution Support Integration of EssilorLuxottica’s Stellest Lenses in Practice

Monica Jong, Head of Medical Affairs North America at EssilorLuxottica, discussed recent findings on Stellest lenses' effectiveness in controlling myopia progression. A two-year randomized clinical trial involving 159 US children showed a 71% reduction in myopia progression compared to single-vision lenses, with 34% of wearers experiencing no progression. The study, published in JAMA Ophthalmology, supports the FDA-approved status of the lenses. Additionally, the American Medical Association recently passed a resolution classifying myopia as a formal disease, including Stellest lenses as a treatment option for children aged 6-12 years. This classification may support insurance coverage for pediatric eye care. EssilorLuxottica stated it has trained over 30,000 eye care professionals on myopia management.